Latest Neuropsychiatry News

Entropy Neurodynamics has received a $1.73 million R&D tax incentive refund from the Australian Government, reinforcing its clinical development of an intravenous psilocin treatment for neuropsychiatric disorders.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Entropy Neurodynamics has successfully enrolled and dosed the first patient in its pioneering clinical trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder, while securing $6.1 million in new funding to accelerate development.

Tryptamine Therapeutics has raised $6.1 million to fast-track clinical development of its IV-infused psilocin drug TRP-8803, targeting binge eating disorder and other neuropsychiatric conditions.